Human immunodeficiency Virus (HIV)

CAS No.	Product Name	Inquiry
2249755-49-3	A3N19 A3N19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with an EC50 of 3.28 nM against HIV-1 IIIB.
2249814-82-0	Dolutegravir-d5 Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
2253744-59-9	KRH-3955 hydrochloride KRH-3955 hydrochloride is an orally bioavailable CXCR4 antagonist, and a highly potent and selective inhibitor of X4 HIV-1, with an EC50 of 0.3-1.0 nM. It inhibits the binding of CXCR4 to SDF-1α with an IC50 of 0.61 nM.
226700-79-4	Fosamprenavir Fosamprenavir, also called as GW433908, Lexiva and Telzir, is an oral prodrug of the protease inhibitor (PI) amprenavir. Combined with other antiretroviral agents, Fosamprenavir is indicated for the treatment of patients with HIV infection, particularly those who have not previously received antiretroviral therapy.
226700-81-8	Fosamprenavir Calcium Salt HIV protease inhibitor; water soluble prodrug of amprenavir.
229005-80-5	TAK-779 TAK-779 is a potent, dual antagonist at chemokine receptors CCR2 and CCR5 with IC50 = 1.4 nM at CCR5 and 2.3 nM at CCR2. Antagonists of both CCR2 and CCR5 such as TAK-779 have been investigated for treatment of viruses, rheumatoid arthritis, multiple sclerosis, and cancer. CCR5 is particularly targeted for anti-HIV therapy, since HIV entry into cells requires chemokine coreceptors CCR5 and CXCR4.
229975-97-7	Atazanavir Sulfate Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM. It is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus.
2302046-54-2	HIV-1-inhibitor-27 HIV-1 inhibitor-27 (compound 5) is a potent HIV-1 inhibitor with IC50s of 16 μM, 0.5 μM and 0.39 μM for HIV-1 YU2, NL4-3 and 89.6 strain, respectively. HIV-1 inhibitor-27 has low cytotoxicity with a CC50 of 128 μM in TZM-bl cells. HIV-1 inhibitor-27 can be used for researching AIDS.
2309699-17-8	Mavorixafor trihydrochloride Mavorixafor trihydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. It also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with IC50s of 1 and 9 nM, respectively.
231957-54-3	MIV-150 MIV-150 is an allosteric inhibitor of HIV-1 and HIV-2 reverse transcriptase with both EC50 values of 1 nM in vitro.
23214-92-8	Daunorubicin EP Impurity D (Doxorubicin) Doxorubicin is an anthracycline antibiotic produced in Str. peucetius var. caesinus. Doxorubicin has anti-Gram-positive bacteria activity and has a broad anti-tumor spectrum. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
2377151-10-3	ZL0580 ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter.
2380001-43-2	Reverse transcriptase-IN-1 Reverse transcriptase-IN-1 is a potent and orally active HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC50 of 13.7 nM against HIV-1 reverse transcriptase enzyme. It has antiviral activity with EC50s of 3.4, 4.3 and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively.
2395777-43-0	HIV-1-inhibitor-33 HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM for HIV-1 and a CC50 of 18 M in MT-4 cells. HIV-1 inhibitor-33 can be used for researching AIDS.
2395777-45-2	HIV-1-inhibitor-34 HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 M in MT-4 cells. HIV-1 inhibitor-34 can be used for researching AIDS.
24027-80-3	2',3'-Dideoxyadenosine 5'-Triphosphate ddATP is an inhibitor of reverse transcriptases from retroviruses, such as HIV-1 and visna (Kis = 20 and 37 nM, respectively). ddATP is commonly used to terminate chain extension produced by the Taq polymerase for its competitive effect with dATP in cells.
2408729-03-1	HIV-IN-4 HIV-IN-4 (Compound 12) is a potent inhibitor of HIV. HIV-IN-4 shows promising anti-HIV activities.
2411819-82-2	NBD-14270 NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100M).
2414099-82-2	HIV-1-inhibitor-39 HIV-1 inhibitor-39 (compound 3c) is a potent HIV-1 inhibitor with an EC50 of >112.88 µM. HIV-1 inhibitor-39 shows anti-RT (HIV-1 reverse transcriptase) activities with an IC50 of 15.75 µM. HIV-1 inhibitor-39 shows cytotoxicity for MT-4 cells with an CC50 of 112.9 µM.
2415504-88-8	HIV-1-inhibitor-26 HIV-1 inhibitor-26 (compound 9a) is a potent HIV-1 reverse transcriptase (RT) inhibitor with an IC50 value of 1.4 μM. HIV-1 inhibitor-26 has low cytotoxicity with a CC50 of 1486 μM in PBMCs. HIV-1 inhibitor-26 can be used for researching AIDS.

※ Please kindly note that our services are for research use only.